Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105441981> ?p ?o ?g. }
- W2105441981 endingPage "804" @default.
- W2105441981 startingPage "795" @default.
- W2105441981 abstract "Abstract Multiple myeloma (MM) remains incurable and novel treatments are urgently needed. Preclinical in vitro and in vivo evaluations were performed to assess the potential therapeutic applications of human recombinant tumor necrosis factor (TNF)–related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) in MM. TRAIL/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. TRAIL/Apo2L also overcame the survival effect of interleukin 6 on MM cells and did not affect the survival of peripheral blood and bone marrow mononuclear cells and purified B cells from healthy donors. The status of the TRAIL receptors (assessed by immunoblotting and flow cytometry) could not predict TRAIL sensitivity of MM cells. The anti-MM activity of TRAIL/Apo2L was confirmed in nu/xid/bg mice xenografted with human MM cells; TRAIL (500 μg intraperitoneally daily for 14 days) was well tolerated and significantly suppressed the growth of plasmacytomas. Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Nuclear factor (NF)-κB inhibitors, such as SN50 (a cell-permeable inhibitor of the nuclear translocation and transcriptional activity of NF-κB) or the proteasome inhibitor PS-341, enhanced the proapoptotic activity of TRAIL/Apo2L against TRAIL-sensitive MM cells, whereas SN50 reversed the TRAIL resistance of ARH-77 and IM-9 MM cells. Importantly, normal B lymphocytes were not sensitized to TRAIL by either Dox, SN50, or PS-341. These preclinical studies suggest that TRAIL/Apo2L can overcome conventional drug resistance and provide the basis for clinical trials of TRAIL-based treatment regimens to improve outcome in patients with MM." @default.
- W2105441981 created "2016-06-24" @default.
- W2105441981 creator A5010021766 @default.
- W2105441981 creator A5012712111 @default.
- W2105441981 creator A5027328800 @default.
- W2105441981 creator A5032464400 @default.
- W2105441981 creator A5043526996 @default.
- W2105441981 creator A5081299017 @default.
- W2105441981 creator A5081617768 @default.
- W2105441981 creator A5091207345 @default.
- W2105441981 date "2001-08-01" @default.
- W2105441981 modified "2023-10-16" @default.
- W2105441981 title "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications" @default.
- W2105441981 cites W139500099 @default.
- W2105441981 cites W141464505 @default.
- W2105441981 cites W1481925502 @default.
- W2105441981 cites W1484817497 @default.
- W2105441981 cites W1554322881 @default.
- W2105441981 cites W1599806854 @default.
- W2105441981 cites W1674551699 @default.
- W2105441981 cites W1965583590 @default.
- W2105441981 cites W1980919524 @default.
- W2105441981 cites W1982661150 @default.
- W2105441981 cites W1984709119 @default.
- W2105441981 cites W1987154010 @default.
- W2105441981 cites W1996594340 @default.
- W2105441981 cites W1999941834 @default.
- W2105441981 cites W2008892452 @default.
- W2105441981 cites W2014380713 @default.
- W2105441981 cites W2019465386 @default.
- W2105441981 cites W2038114873 @default.
- W2105441981 cites W2055905844 @default.
- W2105441981 cites W2056217426 @default.
- W2105441981 cites W2068406884 @default.
- W2105441981 cites W2077793109 @default.
- W2105441981 cites W2084733813 @default.
- W2105441981 cites W2086247747 @default.
- W2105441981 cites W2101759139 @default.
- W2105441981 cites W2104473825 @default.
- W2105441981 cites W2106284224 @default.
- W2105441981 cites W2130988210 @default.
- W2105441981 cites W2156853211 @default.
- W2105441981 cites W2165980203 @default.
- W2105441981 cites W2292093022 @default.
- W2105441981 cites W2323955045 @default.
- W2105441981 cites W2329703437 @default.
- W2105441981 cites W2339091398 @default.
- W2105441981 cites W3145716452 @default.
- W2105441981 cites W4238509480 @default.
- W2105441981 cites W42909849 @default.
- W2105441981 cites W53629506 @default.
- W2105441981 doi "https://doi.org/10.1182/blood.v98.3.795" @default.
- W2105441981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11468181" @default.
- W2105441981 hasPublicationYear "2001" @default.
- W2105441981 type Work @default.
- W2105441981 sameAs 2105441981 @default.
- W2105441981 citedByCount "361" @default.
- W2105441981 countsByYear W21054419812012 @default.
- W2105441981 countsByYear W21054419812013 @default.
- W2105441981 countsByYear W21054419812014 @default.
- W2105441981 countsByYear W21054419812015 @default.
- W2105441981 countsByYear W21054419812016 @default.
- W2105441981 countsByYear W21054419812017 @default.
- W2105441981 countsByYear W21054419812018 @default.
- W2105441981 countsByYear W21054419812019 @default.
- W2105441981 countsByYear W21054419812020 @default.
- W2105441981 countsByYear W21054419812021 @default.
- W2105441981 countsByYear W21054419812022 @default.
- W2105441981 countsByYear W21054419812023 @default.
- W2105441981 crossrefType "journal-article" @default.
- W2105441981 hasAuthorship W2105441981A5010021766 @default.
- W2105441981 hasAuthorship W2105441981A5012712111 @default.
- W2105441981 hasAuthorship W2105441981A5027328800 @default.
- W2105441981 hasAuthorship W2105441981A5032464400 @default.
- W2105441981 hasAuthorship W2105441981A5043526996 @default.
- W2105441981 hasAuthorship W2105441981A5081299017 @default.
- W2105441981 hasAuthorship W2105441981A5081617768 @default.
- W2105441981 hasAuthorship W2105441981A5091207345 @default.
- W2105441981 hasBestOaLocation W21054419811 @default.
- W2105441981 hasConcept C137061746 @default.
- W2105441981 hasConcept C150903083 @default.
- W2105441981 hasConcept C17991360 @default.
- W2105441981 hasConcept C185592680 @default.
- W2105441981 hasConcept C190283241 @default.
- W2105441981 hasConcept C202751555 @default.
- W2105441981 hasConcept C203014093 @default.
- W2105441981 hasConcept C207001950 @default.
- W2105441981 hasConcept C2776364478 @default.
- W2105441981 hasConcept C2777478702 @default.
- W2105441981 hasConcept C2780007613 @default.
- W2105441981 hasConcept C502942594 @default.
- W2105441981 hasConcept C553184892 @default.
- W2105441981 hasConcept C55493867 @default.
- W2105441981 hasConcept C71924100 @default.
- W2105441981 hasConcept C86803240 @default.
- W2105441981 hasConcept C98274493 @default.
- W2105441981 hasConceptScore W2105441981C137061746 @default.
- W2105441981 hasConceptScore W2105441981C150903083 @default.